Caplight Directory>Companies>Code Biotherapeutics-preview>Code-bio


Code Biotherapeutics

Code Biotherapeutics

Private
Hatfield, PennsylvaniaHealthcare & Life Scienceswww.codebiotx.com

Last Round

Series A

Jun 7, 2022

Total Funding Raised

$85M

Momentum Score

25 /100

Company Overview

Code Bio is a biotechnology company specializing in non-viral gene therapies aimed at treating serious and life-threatening genetic disorders through its innovative 3DNA delivery platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

non-viral gene therapy3DNA® delivery platformgenetic medicine deliverygene delivery platformnon-viral vectortargeted deliverylarge payload deliveryAAV alternativere-dosable therapysynthetic vectorDuchenne Muscular DystrophyDMDType 1 DiabetesT1Drare disease therapybiopharma partnerships

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Code Biotherapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Code Biotherapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series AJun 7, 2022
SeedApr 20, 2021
View all Funding Rounds

Key People

Founding team and executive leadership

John Tattory

Consulting CFO

Executive Team

Code Biotherapeutics Investors

Notable investors and investment history

InvestorRounds
UCB VenturesSeries A
CureDuchenne VenturesSeed, Series A
New Enterprise Associates (NEA)Series A, Seed
Hatteras Venture PartnersSeries A
4Bio CapitalSeries A, Seed
Amgen VenturesSeries A
JDRFSeries A, Seed
View all Investors

Code Biotherapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Code Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Code Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersHatfield, Pennsylvania
Employee Range21
Year Founded2020
Last FundingJun 7, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.